$ALKS SEC Filings

Received 9,164 shares by exercise or conversion · Gave up 4,069 shares to cover exercise price or tax ($163K)

Granted 7,239 Restricted Stock Unit Award · Granted 17,998 Non Qualified Stock Option (Right to Buy)

Sold 2,034 shares ($83.5K)

Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

No securities owned

DUBLIN, Sept. 16, 2026 — Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Anne C. Whitaker, to the company’s Board of Directors (the Board). Ms. Whitaker is a seasoned biopharmaceutical executive...

Sold 2,034 shares ($97.7K)

Received 5,000 shares by exercise or conversion ($123K) · Sold 9,000 shares ($423K)

Sold 7,576 shares ($373K)

Granted 217,534 Employee Stock Option (Right to Buy)

Received 44,472 shares by exercise or conversion ($2.08M) · Sold 44,472 shares ($2.24M)

Received 5,000 shares by exercise or conversion ($122K) · Sold 9,000 shares ($437K)

Sold 2,034 shares ($98.8K)